SCHEDULE

We have scheduled our Programs dividing them into Day 1, Day 2, Day 3 in order to make it convenient for you to attend in absolute comfort.

25 Jan
Day 1

Keynote 1

W Patrick Murphy, CO-CEO

Can.bio.io, LLC, Sergeant Bluff, Iowa ,USA

Title: The world-wide medical marijuana phenom

No Image
Biography:

The Colombia and Iowa companies, Kannt SAS and Canb.io mission is to produce organic pharmaceutical grade oil and provide free medicine to Colombians and Iowans.  The growth of the company is currently expanding in Ecuador, Uruguay, Peru, Brazil, Argentina and Chile.  The USA operations include the states of Iowa, Missouri, Nebraska, South Dakota, Kansas and Missouri.

 

Keynote 2

Dr.Darshan Perera

Colombo Institute of Research & Psychology (CIRP) ,Sri Lanka

Title: Grow beyond your brain.

No Image
Biography:

Dr. Darshan Perera from Colombo Institute of Research and Psychology, CIRP visited MIPSTAR today. He met all our staff, talked about mental health challenges in the Maldives and Srilanka. He described the facilities and services available at MIPSTAR being at per with what is available in countries like U.K. He also expressed interest in future collaboration for research as well as training of staff and students.

Abstract:

“Don’t be a slave of your mind” is a famous quote used in advising people to help them resist their urges and impulses. But are we a slave of our mind ? Does that mean the mind could enslave itself? Our ability to comprehend the idea that we could be a slave of our mind, may hint that actually it is not the mind, but something else that is trying to enslave us. What is it? Best possible guess is the brain. It seems the brain is trying to enslave us by enslaving our mind. (Subjected to the debate are we our mind?) Brain with its hard wiring that resulted from years of conditioning and all other forms of learning since our birth and natural reflexes and inherited survival information seem to be providing suggestions about how we should respond to situations mentally and behaviorally. Our ability to think about these thought (Known as theory of mind) further suggest that mind is not actually analyzing its own thoughts but is analyzing the suggestions provided by the brain. Brain is an automated suggestion production machine subjected to  its predictive capacity based on the past experiences, with the primitive logic that probability is the best predictor. That makes  brain nothing better than a super computer.

If what differentiates us humans from the other organisms is the mind (consciousness) , it makes perfect sense to believe that it is not the brain development that differentiates us from other organisms but our ability to recognize impulses and urges as a production of the brain (materialistic body).  Therefore impulse control is a actually the fight of the mind against the brain. Transcendence  could be further detachment of mind from the brain where you see your biological urges and conditioned responses as a part of your materialistic body thus realizing what brain tells us is not necessarily right or wrong. Enlightenment or complete mental well-being must be mind existing unaffected by body, where brains yelling of pain, anger, desire and comfort is heard yet not responded to by the mind. Thus It seems the direction of clinical psychology should focus more on how mind could control brain rather than how brain controls mind or trying to find ways mind and brain could co-exist rather than using brain activity to explain mind or trying  to solve behavioral issues with brain controlling drugs. Instead we should develop the mind, so it doesn’t get affected by brain. Humans need to grow beyond brain, brain has done its job in evolution. It is the time for the mind to evolve.

Keynote 3

Francesco Di Me

Institute of Biosciences and BioResources-UOS Naples CNR ,Italy

Title: In vitro and in vivo anticancer activity of curcumin standardized extract on mesothelioma

No Image
Biography:

Mr. Di Meo received a bachelor’s degree in biology from University of Salernno and a master’s degree in biotlogy from University of Naples “Federico II”. His current field placement is Institute of Biosciences and Bioresuorces. 

Abstract:

A major limitation of the conventional treatments for cancer is related to serious side effects that chemotherapeutic drugs may cause and to the development of cancer resistance. Some advances in cancer therapies have been currently reached thanks to the introduction of alternative approaches, including the use of several phytochemicals, which are able to significantly reduce tumor progression and to improve healing and survival.

Phytochemicals are bioactive plant compounds, which bestow important anti-cancer properties acting as effective tumor growth reducers with no obvious associated side effects.

Curcumin, normally found in the turmeric of Curcuma Longa Linn, is a naturally occurring phytochemical that has been widely used for centuries for the treatment of several diseases.

In order to take advantages of the beneficial effects that Curcumin may have, numerous attempts have been made to increase its efficacy and bioavailability. To overcome solubility problems our and other groups have previously investigated the bioactivity of Curcumin formulations, among them, the most promising one is represented by the co-administration of Curcumin with Piperine, an alkaloid of black pepper and long pepper. Piperine significantly enhances Curcumin bioavailability by preventing its metabolism through the inhibition of the glucuronidation processes.

We have tested anticancer effect of curcumin and piperine formulations (C3 complex) using human mesothelioma cell lines as model.

Keynote 4

Huang Wei Ling

Medical Acupuncture and Pain Management Clinic ,Brazil

Title: Chakras Energy Deficiency in Late-Life Depression Patients

No Image
Biography:

Huang Wei Ling, born in Taiwan, raised and graduated in medicine in Brazil, specialist in infectious and parasitic diseases, a General Practitioner and Parenteral and Enteral Medical Nutrition Therapist. Once in charge of the Hospital Infection Control Service of the City of Franca’s General Hospital, she was responsible for the control of all prescribed antimicrobial medication and received an award for the best paper presented at the Brazilian Hospital Infection Control Congress in 1998. Since 1997, she works with the approach and treatment of all chronic diseases in a holistic way, with treatment guided through the teachings of Traditional Chinese Medicine and Hippocrates.

Abstract:

Statement of the Problem: Late-life depression refers to a major depressive episode occurring for the first time in an older person (usually over 50 or 60 years of age). According to Traditional Chinese Medicine (TCM), depression is associated with deficiency of Yin, Yang, Qi or/and Blood energies, or a combination between these four energy deficiencies.

Purpose:  To address that depression has an energy deficiency cause, diagnosed through the chakras measurement.

Methods: 80 years old woman, suffering from late-life depression since her 60’s, and using antidepressant medication since then. The patient was not able to be functional (inability to leave the house, unable to cook for herself, extreme fatigue and with low self-stem). The patient complained that her symptoms were not improving, even with the increase of the dosage of the antidepressant drugs. According to TCM, her diagnosis was Kidney-Yang and Blood deficiency. Chinese dietary counselling, acupuncture and moxibustion were started. She also performed measurement of the chakras, considering a scale of 1 to 8, 1 being the minimum and 8 the normal level, six of her seven chakras were measured in 1. To replenish the energy of the chakras, she also used crystal-based medication and homeopathy based on the Constitutional Homeopathy of the Five Elements based on TCM theory. She was oriented to gradually withdrawn the antidepressant medication, always associating the acupuncture sessions to reduce withdrawn symptoms

Keynote 5

Najib Kissani

Vice President of IBE (International Bureau of Epilepsy) ,Morocco

Title: Terminology of epilepsy in Morocco & developing countries and its consequences

No Image
Biography:

Prof. Najib Kissani/Head of Neurology Department- Vice President of IBE (International Bureau of Epilepsy) is a Simple mind person, very pragmatic, hard working researcher, and sportive man, he like nature, sport, travels, and work Qualified in Rabat medical School, than assistant Professor in casablanca Medical School Degree NameDoctor of Medicine (M.D.)Field Of StudyDegree in Epileptology from Kings College Hospital in London; UK.  Publication: Congenital insensitivity to pain: clinical and neurophysiological study in three sisters of a Moroccan family].

Abstract:

In Morocco, the term of epilepsy is commonly called ‘’ ????? ‘’ «Asaraa », which is usually misunderstood as meaning to our patient and its family that he has more an obsession by an evil spirit than a brain disease.
Our study approached patients suffering of epilepsy and their families for a year in our specialized out-patient clinics in Marrakech 3rd level hospital (Morocco), covering 300 patients and 180 accompanying persons.  The results showed that our patients and their carers have 14 designations in our spoken Arabic language to define epilepsy.
We found names such as «Msetti » (crazy), « maskoune » « fihleriah » (obsessed by an evil spirit). This lexicon describing epilepsy is very rich, always pejorative, negative, and refers to the clichés that remain immovable even with the progress of medicine.
And overall, the social dimension of epilepsy is clearly further than the etiological and nosographic representations of this disease. Therefore, people with epilepsy suffer more from prejudices that surround them so they feel marginalized, expelled from school, difficulty in finding jobs. This is due to ignorance of the causes and the potential of therapy.
Doctors and sociologists continue to underline the greatest problem facing epileptic patients which is the negative attitude due to the lexicon who describes epilepsy in Arabic countries.
Various obstacles, both from the cultural perception of the disease, the low priority accorded to it by health authorities, deficiencies of the infrastructure and the irregularity in the supply of medications.
Our work highlights the confusion that the terminology does. So we try to found the most suitable
translation and closer to the true meaning of the pathology, we suggest «??? ?????? » (falling
disease) or «???? ?????» (behavioral stop) or « ???????? » (epilepsy).

Speaker 1
No Image
Biography:

Dr. Deidiane Elisa Ribeiro is a post doctoral student at the Chemistry Institute of the University of São Paulo, Brazil. She received a bachelor’s degree in Pharmaceutical Sciences from Federal University of Alfenas (Brazil) and a master’s degree in Sciences from the Departament of Pharmacology, University of São Paulo (Brazil). Dr. Ribeiro also received double doctorade’s degree: in Sciences from the Departament of Pharmacology, University of São Paulo (Brazil) and in Health Sciences from the Faculty of Health, Aarhus University (Dinamarca). Her research interests include Alzheimer’s disease, humor disorders and purinergic signaling.

Abstract:

Beyond memory loss and cognitive impairment, patients with Alzheimer’s disease (AD) frequently develop neuropsychiatric symptoms such as depression. Depression affects up to 50% of AD patients and has a severe negative impact in their lives. However, treatments currently available for AD mainly aim to improve some of the cognitive symptoms and are not disease-modifying. Thereby, elucidating the mechanisms underlying depression in AD may reveal novel avenues for progress in its therapy. AD and depression share common pathological features such as: neuroplasticity impairment, decreased BDNF levels, enhanced glutamate release and neuroimmune response activation, mainly in the hippocampus and prefrontal cortex. These processes can be stimulated by the P2X7 receptor (P2X7R) activation, an ATP-gated cation channel widely expressed in the central nervous system. Accordingly, P2X7R blockade ameliorates both molecular and behavioral alterations related to AD and depression. Thus, P2X7R antagonists may be considered as an alternative for the treatment of both cognitive impairment and depressive symptoms of AD. Keywords: Alzheimer’s disease, depression, P2X7 receptor.

Speaker 2

Osman Toktas

Van Yüzüncü Y?l University ,Turkey

Title: Ingested foreign objects in dementia patients

No Image
Biography:

Osman Toktas is an Assosiate Professor in the Department of General Surgery at  Yuzuncu Yil University, Turkey.

Abstract:

BACKGROUND:

The aim of the present study was to review cases that required surgical intervention to remove ingested foreign bodies.

METHODS:

Medical records of 7 patients who underwent surgical intervention at the Yüzüncü Y?l University Department of General

Surgery between 2009 and 2014 after ingesting foreign bodies were reviewed.

Keywords: Foreign body; ingested; laparoscopy; laparotomy; surgical intervention.

Speaker 3
No Image
Biography:

Ms. is a second year PharmD student at the University of British Columbia. She received a bachelor’s degree in Life Sciences with a minor in Nutritional Sciences from the University of British Columbia in Vancouver, Canada and a Master’s of Public Health from the University of Western Ontario in London, Canada. Her research focuses on public health pharmacy and  pharmacotherapy, susbtance use disorder and addiction care, behavioural and brief interventions, and implementation science. Her current research focuses on opioid agonist treatments and cognitive impairment. 

Abstract:

Background: Throughout the recent years, trends of opioid use have changed among people living with dementia. There has also been a rise in duration and frequency of opioid analgesics use among those patients. Although the safety and efficacy of such medications have been assessed by several studies, there is still a gap in literature in terms of the major contributing factors and associated comorbidities that have contributed to the observed trends. Objective: This review aimed to investigate the opioid use trends among patients with dementia to find the common themes and key findings of evidence on this topic. Methods: A comprehensive search was conducted across five databases including Ovid-Medline, PsycINFO, Embase, CINAHL, and Web of Science. Studies were included if; (1) they were peer-reviewed; (2) they included qualitative data; (3) they were published from 2009 to 2019; (4) populations were exclusive to patients with dementia. Following the conduction of quality assessment, extracted data were thematically analyzed utilizing qualitative data analyzing software. Results/Conclusion: (in progress). (166 words).

Speaker 4
No Image
Biography:

Dr. Siddhartha Mondragón-Rodríguez graduated in Chemical Engineering from Michoacán University of Saint Nicolas of Hidalgo (UMSNH) in 1996 - 2002. Master’s Degree (MsC) in Molecular Biomedicine from National School of Medicine from the National Polytechnic Institute of Mexico City in 2003 - 2005. PhD from Center of Research and Advanced Studies of the National Politechnical Institute in 2005 – 2009. During this time, he analyzed the relationship between the amyloid beta protein (Ab) and the neurofibrillary tangles built from phosphorylated tau protein in human Alzheimer´s brains, the most important proteins known to be related to Alzheimer´s disease (AD). Research Invited at Case Western Reserve University, Department of Pathology, Cleveland, Ohio, US, in 2006 - 2007. Where he aimed to compare his AD findings to other tau related neurological diseases such as Pick disease, Fronto-temporal dementia, Progressive Supranuclear Palsy and Parkinson’s disease. He was a H.H. Jasper postdoctoral Fellow from Universite de Montreal in 2009 - 2012. Faculte de Medecine, Departament de Physiologie., Montreal, Qc, Canada. At that time, he aimed to unveil the relationship between phosphorylated tau protein and one of the most fundamental events in the brain, synaptic plasticity and its long-lasting forms (LTD and LTP) who have been proposed to be affected by Ab during AD. Then, he obtained the Fonds du recherche du santé du Quebec postdoctoral fellowship at McGill University, Faculte de Medicine, Department of Psychiatry, Montreal, QC, Canada from 2012 to 2014. That allowed him to study the brain network alterations during neurodegeneration. Since 2014, he moved to the Department of Developmental Neurobiology and Neurophysiology, where he is currently studying the role of tau phosphorylation in brain network communication

Abstract:

For many years, the field of Alzheimer’s disease (AD) has focused on two main hypotheses positing amyloid beta (Aβ) and tau phosphorylation (pTau) as key pathogenic mediators. In line with these hypotheses, several groups have shown that the sinaptotoxicity in AD depends mainly on an increase in pTau levels. Confronting this leading hypothesis, we reported that the increase in phosphorylation levels of dendritic Tau, at its microtubule domain (MD), acts as a neuroprotective mechanism, that prevents Nmethyl-D-aspartate receptor (NMDAr) overexcitation. Further supporting this alternative role of pTau, we have recently shown that early increases in pTau close to MD sites prevents hippocampal circuit overexcitation in a transgenic AD mice model. Altogether, we propose that Tau protein phosphorylated near MD sites is involved in neuroprotection, rather than in neurodegeneration. Keywords: Tau, phosphorylation, theta activity, epileptiform activity, receptor overexcitation, and compensatory mechanism.

Speaker 5
No Image
Biography:

Dr. Petkova-Kirova is an Associate Professor at Institute of Neurobiology, Bulgarian Academy of Sciences (INB,BAS), Bulgaria. She received her master degree in biochemistry from Sofia University, Bulgaria and her PhD in electrophysiology at the Institute of Biophysics, BAS, Bulgaria. She has specialized as an Alexander von Humboldt Fellow in MPI for Experimental Medicine, Gottingen, Germany and in the University of Pittsburgh, Pittsburgh, USA. For the last 6 years she has been working in the Saarland University, Saarbruecken, Germany and since recently in INB, BAS, Bulgaria on neuropeptides and their interactions with neurotransmitters involved in disorders like schizophrenia, depression and others.

Abstract:

Schizophrenia is a severe psychiatric disorder that affects 1% of the population and includes cognitive, emotional and behavioural disturbances. Despite substantial advances in schizophrenia research, the underlying pathophysiology of the disease remains largely obscure and currently used antipsychotic drugs (APDs) have a number of disadvantages. Neurotensin (NT) is a tridecapeptide originally isolated from bovine hypothalamus. Based on several lines of evidence including the striking similarity between the behavioral and functional effects of systemically administered APDs and those of centrally administered NT, the latter has been postulated to be an endogenous antipsychotic. The present research studies which receptors are involved in NT effects (NT-induced changes in central nervous system neurotransmitters like dopamine and serotonin and others) in prefrontal cortex, a target of atypical APDs. Atypical APDs have high affinities for a number of dopaminergic, serotonergic, adrenergic and muscarinic receptors but the activation or inhibition of which of them is particularly beneficial for the treatment of schizophrenia is not completely clear. A comparison of the pharmacological profile of NT with that of atypical APDs sheds light on the problem. The pharmacology of NT could also serve as a model for the design of new, more efficient and better tolerated drugs. In view of the emotional and behavioural disturbances characteristic of schizophrenia, amygdal? is an important objective in studying the disease. Amygdala is rich in NT terminals and receptors and the role of NT in amygdala will also be studied. In vivo brain microdialysis combined with HPLC determination of brain neurotransmitters is used. Keywords: schizophrenia, neurotransmitters, neurotensin , in vivo brain microdialysis

  • Europe : +44 2039665767
    Asia : +91 4048571057
    dementia@magnuscorpus.com
  • Subscribe To Newsletter